Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients
- 21 July 2014
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (2) , 343-352
Abstract
Aim: Our aims were to quantify ganciclovir pharmacokinetics in paediatric and adult kidney, liver and lung transplant patients taking a range of valganciclovir doses to prevent herpes virus infections, including a 450 mg regimen, and to identify sources of pharmacokinetic variability.Method: Plasma samples were collected at 2, 4, 8 and 12 weeks post‐transplant and at 4, 6, 8 and 12 months post‐transplant in subjects prescribed longer courses. Ganciclovir was measured by liquid chromatography/ultraviolet detection. Non‐linear mixed effects modelling was used to analyze the concentration–time data and evaluate demographic and transplant‐related covariates.Results: A two compartment model with first order absorption best described the data. Given the range of body sizes, clearance and volume of distribution terms were scaled using standard weight‐based allometric exponents. Creatinine clearance was included on apparent oral clearance. Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h−1, 87.5 l, 4.80 l h−1 and 42.6 l, respectively. The median terminal half‐life for kidney, liver and lung transplant recipients was 9.4, 9.5 and 8.2 h, respectively. Median exposure (i.e. AUC(0,∞) in subjects taking valganciclovir 900 mg or 450 mg once daily was 57.4 and 34.3 μg ml−1 h, respectively.Conclusion: Allometric scaling allowed simultaneous analysis of data from children and adults. Ganciclovir pharmacokinetics were similar among kidney, liver and lung transplant recipients. Ganciclovir exposure after valganciclovir 450 mg once daily may be suboptimal in some individuals and requires evaluation along with virologic outcomes data.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (2 P01 DK13083-40A)
- University of Minnesota Graduate School (Doctoral Dissertation Fellowship Award)
- University of Minnesota International Center for Antiviral Research and Epidemiology
This publication has 39 references indexed in Scilit:
- The Relationship between Drug Clearance and Body SizeClinical Pharmacokinetics, 2012
- GFR-estimating models in kidney transplant recipients on a steroid-free regimenNephrology Dialysis Transplantation, 2010
- The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus diseaseClinical Pharmacology: Advances and Applications, 2009
- Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral ValganciclovirAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant RecipientsAmerican Journal of Transplantation, 2008
- A Size Standard for PharmacokineticsClinical Pharmacokinetics, 1996
- In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovirDiagnostic Microbiology and Infectious Disease, 1987
- A simple estimate of glomerular filtration rate in adolescent boysThe Journal of Pediatrics, 1985
- A simple estimate of glomerular filtration ratein full-term infants during the first year of lifeThe Journal of Pediatrics, 1984
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976